Exabis Library
Welcome to the e-CCO Library!
P414 Risk factors for the development of anti-drug antibodies to infliximab and adalimumab in Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P414: Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn´s disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P414: Loss of response to anti-TNF in inflammatory bowel disease in a Portuguese centre
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P414: Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P414: Stoma in patiens with IBD: friend or foe? -\tEffect of stoma on course of disease, psychological well-being and working capacity
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P414: Usefulness of ultrasonography in the assessment of postoperative recurrence of Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P414: Ustekinumab endoscopic response at Week 16 is associated with early normalisation of faecal calprotectin after induction
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P414: Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn’s disease refractory or intolerant to anti-TNF: a multicentre Italian study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P415: Dose escalation of adalimumab and related prognostic factors in patients with Crohn's disease treated with adalimumab maintenance therapy: A single-centre, five-year cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P415: Improving food‐related quality of life in Inflammatory Bowel Disease with a novel web-based intervention: a randomised controlled feasibility trial
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P415: Paradoxical onset of Takayasu’s arteritis in patients with inflammatory bowel disease treated with anti-tumour necrosis factor-α agents
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P415: Predictive factors of a subsequent ano-perineal abscess in patients with fistulising ano-perineal Crohn’s disease in remission
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P415: Real-world data in Inflammatory Bowel Diseases on vedolizumab therapy: Interim analysis of the non-interventional LISTEN II study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P415: Therapeutic drug monitoring of thiopurines in the management of Asian patients with inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P415: Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P416 Results of the first paediatric randomised controlled trial of faecal microbiota transplant for ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P416: Addition of oral antibiotics to mechanical bowel preparation significantly improves anastomotic healing after ileocolic resection for Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P416: An online educational portal is effective in improving knowledge regarding reproduction and IBD
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P416: Faecal calprotectin can predict mucosal healing in patients with inflammatory bowel diseases treated with vedolizumab: a prospective single-centre study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM